Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
about
Tuberculosis: opportunities and challenges for the 90-90-90 targets in HIV-infected childrenGetting to 90-90-90 in paediatric HIV: What is needed?Understanding pharmacokinetics to improve tuberculosis treatment outcome.Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.Key toxicity issues with the WHO-recommended first-line antiretroviral therapy regimen.Influence of efavirenz pharmacokinetics and pharmacogenetics on neuropsychological disorders in Ugandan HIV-positive patients with or without tuberculosis: a prospective cohort study.Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE studyEfavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionThe impact of genetic polymorphisms on the pharmacokinetics of efavirenz in African childrenRifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.CYP2B6 genotype, but not rifampicin-based anti-TB cotreatments, explains variability in long-term efavirenz plasma exposure.Antiretroviral treatment in HIV-infected children who require a rifamycin-containing regimen for tuberculosis.Is there a need to increase the dose of efavirenz during concomitant rifampicin-based antituberculosis therapy in sub-Saharan Africa? The HIV-TB pharmagene study.Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.Antiretroviral Treatment and Resistance Patterns in HIV-Infected Children.Pharmacokinetics of efavirenz in patients on antituberculosis treatment in high HIV and tuberculosis burden countries: a systematic review.
P2860
Q26774267-8DB5FB6D-6578-4DB4-A5D3-E9E60CC55025Q30385352-CE6E9ED5-A7A6-46DA-81DE-E67488912677Q30411703-C0343B1B-1F34-4A6F-8A2D-E42717CC35A6Q33798516-577237B1-D25E-4583-AD02-82BC8BF02A1AQ34455442-038EBF99-A066-46F8-B8A8-120D6ADE7AF9Q34536677-375F359A-21EC-421E-B3F0-3A76446A4802Q34756398-CE4988C0-C1C1-43B1-A9EF-CDAB6FCECE70Q35547048-36489D5C-4276-440B-B101-86DDD4B6A741Q35846143-CBFEF16C-FE83-4938-BAA6-5CB5556383BFQ35974648-01B994DB-113B-4328-83A9-AFAC08B4A1C2Q36094233-2A1A1C30-D967-4503-A5EC-07FC3AF5F26FQ37030715-84D5E417-E64C-4F6B-8096-182A315A6944Q37153012-4B023988-7F5E-477C-88A6-22B8EACE111FQ37519804-B3ED8C31-1D2F-46C3-B755-1687317C6BDAQ37617319-40D1AEE6-0EE7-4A8D-968F-383F8F2F7033Q37626582-B9D7A47A-7D67-4CF2-86DA-E2A499D28B14Q38861140-5FA778C1-E922-4946-BA24-2B5BDB8C3872Q38874266-B0535E5A-AF51-4922-A661-47EBAB371E29Q39039468-EA3A9E4A-945A-4575-9552-57E88E40F99FQ40694902-4483ACBF-2AA0-4413-BC09-EFAE089F0159Q41026791-CDEA8F8D-2B5B-4B54-83F6-5643377D1E9CQ52330065-6DDF05B2-1921-4C55-A923-77559688CB2A
P2860
Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@en
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@nl
type
label
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@en
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@nl
prefLabel
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@en
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@nl
P2093
P2860
P50
P1433
P1476
Effects of rifampin-based anti ...... ldren vary by CYP2B6 genotype.
@en
P2093
Brian Eley
Concepta Merry
David W Haas
Hermien Gous
James J C Nuttall
Peter Smith
Phumla Sinxadi
P2860
P304
P356
10.1097/QAD.0B013E328360DBB4
P407
P577
2013-07-01T00:00:00Z